A newly formed organization of legal experts and industry insiders will try to change the view on the cannabis market, thanks to the launch of the National Association of Cannabis Businesses (NACB) a self-regulatory agency for the industry in the US.
Despite the success stories in the cannabis landscape, there have been recent instances of critics calling out some light regulation or obscure business practices. This has lead to the June 15th launch NACB in the US–an organization that seeks to act as a regulatory body for the infant industry.
NACB will offer help to businesses associated with them to establish “voluntary national standards,” which the group says will address advertising and financial integrity.
“The launch of the NACB comes as the industry is experiencing significant growth, with sales of cannabis products nearing $7 billion in 2016 and estimated to reach $50 billion by 2026,” a statement from the association read.
Andrew Kline, who has served as a special counsel for the Federal Communications Commission since January 2016, will be the president of this new organization.
The role of the NACB
“[W]e will deliver best-in-class services to help the industry seize its full growth potential, including the development of national standards and access to a group of executives and advisors with deep experience across various highly regulated industries,” Kline said in the statement.
“In addition to access to our team, we plan to offer tools and services that will help our members to grow their businesses, including first-in-class technology,” he continued.
The group promised to establish an “ultra-secure” technology platform powered by an IBM (NYSE:IBM) infrastructure, to “demonstrate the transparency banks and investors require in order to conduct business with the cannabis industry.” The launch is expected to be revealed later this year.
Founding member and CEO of Etain a manufacturer of medical marijuana products–Amy Peckham, said the group will allow the industry to reach a much-needed level of transparency in order to “become legitimately recognized for the contributions cannabis has to offer to our society and economies.”
Despite the growth stories from the cannabis industry, at times companies and experts within the area remind investors just how new this market is. Much like industries before it, the cannabis sector must establish customs and self-regulatory groups. The creation of the NACB bodes well for the industry–if transparency and potent punishments are available in case of wrong doing.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.